These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15744814

  • 1. Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.
    Moon SH, Shin KH, Suh JS, Yang WI, Noh JK, Hahn SB.
    Yonsei Med J; 2005 Feb 28; 46(1):119-24. PubMed ID: 15744814
    [Abstract] [Full Text] [Related]

  • 2. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
    Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG.
    Ann Surg Oncol; 2008 Mar 28; 15(3):906-14. PubMed ID: 18163171
    [Abstract] [Full Text] [Related]

  • 3. [Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children].
    Muñoz Villa A, Ocete G, Aymerich ML, Maldonado S, Otheo E, Calvo M, Amaya J.
    Med Clin (Barc); 1996 Jun 29; 107(5):161-4. PubMed ID: 8758673
    [Abstract] [Full Text] [Related]

  • 4. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-Ariznabarreta L, Benítez J, González-Neira A.
    Pharmacogenomics J; 2009 Oct 29; 9(5):347-53. PubMed ID: 19434073
    [Abstract] [Full Text] [Related]

  • 5. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma.
    Shin KH, Moon SH, Suh JS, Yang WI.
    Clin Orthop Relat Res; 2000 Jul 29; (376):200-8. PubMed ID: 10906876
    [Abstract] [Full Text] [Related]

  • 6. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY, Yen HJ, Yen CC, Chen WM, Chen PC, Wu HT, Chiou HJ, Chang WH, Hsu HE.
    Ann Surg Oncol; 2015 Apr 29; 22(4):1080-7. PubMed ID: 25323470
    [Abstract] [Full Text] [Related]

  • 7. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
    Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD.
    Cancer; 2012 Dec 01; 118(23):5888-93. PubMed ID: 22648705
    [Abstract] [Full Text] [Related]

  • 8. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
    Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, Yamamoto N.
    Anticancer Res; 1998 Dec 01; 18(1B):657-66. PubMed ID: 9584049
    [Abstract] [Full Text] [Related]

  • 9. Outcome of postradiation osteosarcoma does not correlate with chemotherapy response.
    Lewis VO, Raymond K, Mirza AN, Lin P, Yasko AW.
    Clin Orthop Relat Res; 2006 Sep 01; 450():60-6. PubMed ID: 16906104
    [Abstract] [Full Text] [Related]

  • 10. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, Exner GU, Fuchs N, Göbel U, Graf N, Heise U, Helmke K, von Hochstetter AR, Jürgens H, Maas R, Münchow N, Salzer-Kuntschik M, Treuner J, Veltmann U, Werner M, Winkelmann W, Zoubek A, Kotz R.
    Klin Padiatr; 1999 Sep 01; 211(4):260-70. PubMed ID: 10472560
    [Abstract] [Full Text] [Related]

  • 11. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG, Song WS, Cho WH, Kong CB, Cho SH.
    Clin Orthop Relat Res; 2014 Jun 01; 472(6):1911-20. PubMed ID: 24574120
    [Abstract] [Full Text] [Related]

  • 12. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S, Bakhshi S.
    J Surg Oncol; 2015 Nov 01; 112(6):662-8. PubMed ID: 26381138
    [Abstract] [Full Text] [Related]

  • 13. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, Furuse K, Minamizaki T, Kawaguchi N, Yamawaki S.
    J Orthop Sci; 2009 Jul 01; 14(4):397-404. PubMed ID: 19662473
    [Abstract] [Full Text] [Related]

  • 14. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C, Italian Sarcoma Group/Scandinavian Sarcoma Group.
    J Chemother; 2002 Apr 01; 14(2):198-206. PubMed ID: 12017378
    [Abstract] [Full Text] [Related]

  • 15. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ, Wang JW, Chen YJ, Tang Y, Huang CH.
    Chang Gung Med J; 2009 Apr 01; 32(1):72-80. PubMed ID: 19292942
    [Abstract] [Full Text] [Related]

  • 16. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS, Cooperative German-Austrian-Swiss Osteosarcoma Study Group.
    J Clin Oncol; 2003 May 15; 21(10):2011-8. PubMed ID: 12743156
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K.
    Cancer; 2004 Feb 15; 100(4):818-25. PubMed ID: 14770440
    [Abstract] [Full Text] [Related]

  • 18. Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis.
    Wang W, Wang ZC, Shen H, Xie JJ, Lu H.
    Eur Rev Med Pharmacol Sci; 2014 Feb 15; 18(9):1383-90. PubMed ID: 24867518
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
    Jeon DG, Kong CB, Cho WH, Song WS, Cho SH, Choi SW, Lee SY.
    J Surg Oncol; 2014 Mar 15; 109(3):275-9. PubMed ID: 24243222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.